title: [Docetaxel with concurrent radiotherapy in patients with inoperable or relapsed oesophageal cancer].
abstract: BACKGROUND
  In vivo studies have shown docetaxel, a new chemotherapeutic agent, enhances radio-sensitivity by causing a cell cycle arrest in the G2/M phase. We report here to evaluate the efficacy and tolerability of weekly docetaxel concurrent with radiotherapy in advanced or relapsed oesophageal cancer patients.
  
  
  METHODS
  A total of 8 esophageal cancer patients with relapsed mediastinal lymph nodes (6 patients), psychological disease (1 patient) and local advanced tumor (cT4) after initial 5-FU/CDDP therapy (1 patients) received docetaxel (10 mg/m2 weekly) plus concurrent radiotherapy (2 Gy daily, a total dose of 60 Gy).
  
  
  RESULTS
  2 patients achieved a complete response and 5 patients achieved a partial response, for an overall response rate of 87.5%. Median survival length was 13. 3 months and time to disease progression was 6.6 months. No patient experienced grade 3-4 hematological adverse event. There was esophago-mediastinal fistula in 1 patient.
  
  
  CONCLUSIONS
  Docetaxel with concurrent radiotherapy was very effective for relapsed or local advanced esophageal cancer. This therapy had no high grade adverse event and a quality of life in esophageal cancer patients could be maintained.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kubo
authors.forename: Jyunya
authors.initials: J
authors.lastname: Morimoto
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Sakurai
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Muguruma
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Amano
authors.forename: Eiji
authors.initials: E
authors.lastname: Noda
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagahara
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takashima
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yashiro
authors.forename: Nobuya
authors.initials: N
authors.lastname: Yamada
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Onoda
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Maeda
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Sawada
authors.forename: Bunzo
authors.initials: B
authors.lastname: Nakata
authors.forename: Masaichi
authors.initials: M
authors.lastname: Ohira
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel